First Results from the International BPDCN Registry: Data from 36 Patients Across 12 Countries
Gevorg Tamamyan, Editor-in-Chief and Co-Founder of OncoDaily, shared on LinkedIn:
“Here we present the first results from the BPDCN International Registry, established by the Immune Oncology Research Institute.
Title: Blastic plasmacytoid dendritic cell neoplasm (BPDCN): international, multi-center collaboration and global registry program
Authors: Astghik Voskanyan, Maria Badikyan, Marina Konopleva, Alvaro Alencar, Arusyak Ivanyan, Carolyn Owen, Consolato M Sergi, Ching-Tien Peng, Dickran Kazandjian, Justin Taylor, Funda Tekkesin, Hasanein Ghali, Karen Bedirian, Maria Paola Martelli, Enrico Attardi, Maria Teresa Voso, Mariam Abramashvili, Mazin Faisal Al-Jadiry, Michalis Michael, Min-Yu Su, Nare Martirosyan, Nerses Ghahramanyan, Nino Totogashvili, Pavel P Kotoucek, Rejin Kebudi, Robin Ohannessian, Ruzanna Papyan, Shushan Hovsepyan, Salma Elashwah, Sameer Bakhshi, Samvel Bardakhchyan, Samvel Danelyan, Shaimaa El-Ashwah, Tezer Kutluk, Deniz Tuğcu, Ahmad Alhuraiji, Vassilios Lazaris, Gevorg Tamamyan, Naveen Pemmaraju

BPDCN is a rare and aggressive hematologic malignancy. In this initial report, we captured data from 36 patients across 12 countries—a meaningful start for a disease where every case matters.
Since then, the registry has more than doubled in size. New centers and additional countries have joined this growing international effort. Yet for rare malignancies like BPDCN, more is not optional—it is essential. Progress depends on collecting the most comprehensive, global dataset possible.
If you are a hematologist–oncologist, pediatric or adult, anywhere in the world, and you have managed or are managing a BPDCN case, we invite you to join this collaboration.
For rare diseases, collaboration is not an advantage. It is the only way forward.”
Read more from Gevorg Tamamyan on Hemostasis Today.
-
Nov 20, 2026, 17:27Adam Bryant: Great Science, Valuable Connections and a Wonderful Haematology Community at Blood 2026
-
Nov 20, 2026, 17:25Gurpreet Kaurr: Scientific Discussions, New Perspectives and Inspiration at HAEMATOCON 2026
-
Nov 20, 2026, 17:24Bispecific FVIIIa-Mimetic Antibodies in Haemophilia A – CRH French Reference Center for Hemophilia Lyon
-
Nov 20, 2026, 17:23Khalid Rehman: Psychosocial Burden Among Caregivers of Patients with Beta-Thalassemia Major in Pakistan
-
Nov 20, 2026, 17:20Dhinesh Selvaraju: Caplacizumab Becomes the First FDA-Approved Treatment for Pediatric aTTP
-
Nov 20, 2026, 17:19Paris Margaritis: Presenting Preclinical Data on GENV-HEM at the WFH Workshop
-
Nov 20, 2026, 17:18WFH Opens Public Comment on Draft Guidelines for Hemostatic Agents and Prophylaxis
-
Nov 20, 2026, 17:18Ketan Asawale: Consensus on the Management of Cancer-Associated Thrombosis in India
-
Nov 20, 2026, 17:16Ajay Samkaria: The Evolution of Hemostasis Diagnostics with the ACL TOP 70 Series